Calcific Aortic Stenosis
2006; Lippincott Williams & Wilkins; Volume: 114; Issue: 19 Linguagem: Italiano
10.1161/circulationaha.106.657759
ISSN1524-4539
Autores Tópico(s)Coronary Interventions and Diagnostics
ResumoHomeCirculationVol. 114, No. 19Calcific Aortic Stenosis Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBCalcific Aortic StenosisA Disease Ready for Prime Time Nalini M. Rajamannan, MD Nalini M. RajamannanNalini M. Rajamannan From the Division of Cardiology and Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, Ill. Originally published7 Nov 2006https://doi.org/10.1161/CIRCULATIONAHA.106.657759Circulation. 2006;114:2007–2009Calcific aortic stenosis is the number 1 cause for surgical valve replacement in the United States and Europe. In 2006, surgical valve replacement still remains the number 1 indication for the treatment of this disease process, as defined by the American College of Cardiology/American Heart Association guidelines for valvular heart disease by Bonow et al.1 This standard of care for patients with severe symptomatic aortic stenosis requiring surgical valve replacement was defined in 1968 by Ross and Braunwald2 as the main therapy for this disease. For years, this disease has been described as a passive process that develops secondary to serum calcium attaching to the valve leaflet surface to cause nodule formation. Therefore, surgical replacement of the valve is the obvious approach toward relieving outflow obstruction in these patients. Until recently, the lack of experimental models in this field has limited our understanding of the disease.Article p 2065In the middle of the last century, the field of cardiology was in a similar position with our understanding of coronary vascular atherosclerosis. This was summarized in 1942 by Dr James B. Herrick,3 who wrote a short history of cardiology. In the chapter on coronary atherosclerosis, he predicted the future of therapeutic approaches for vascular atherosclerosis. In this textbook, he wrote of heart disease: "This is the story of a bad disease. … The outlook for dread angina it thought to be more favorable than it was first thought … though the cause … has not been discovered, and vascular disease may never be warded off or cured, research may unearth secrets by which premature or old age may be post-poned." In 2006, we are in a unique position to predict that therapeutic approaches for calcific aortic stenosis will be possible with the emergence of models that recapitulate this disease process.After the study by Ross and Braunwald2 and the surgical advances in the field of aortic valve surgery, the next landmark study in the field of valvular heart disease was by Stewart et al,4 which defined the independent risk factors for calcific aortic stenosis, including hypertension, elevated low-density lipoprotein (LDL), male gender, smoking, and diabetes. These findings have been confirmed in many other retrospective databases across the country.5–9 These studies provide the basis that atherosclerotic risk factors play a role in the development of this disease process.The study by Weiss et al10 in this issue of Circulation demonstrates the first experimental evidence that elevated cholesterol in a genetic mouse model causes severe aortic stenosis by echocardiographic measurements and hemodynamic catheterization studies. The study tested the genetic knockout mouse, which lacks the gene for the LDL receptor and expresses only the receptor for the human apolipoprotein B-100 (LDLr−/-ApoB100/100) in an aging genetic mouse model. This genotype is known to be associated with a human atherogenic lipoprotein profile and with the development of atherosclerotic lesions involving 15% to 20% of the aortic intimal surface in the absence of any specific diet.11 This model induces mineralization, as confirmed by Von Kossa staining, which stains for calcium and phosphate mineral. The investigators also measured evidence of oxidative stress by measuring superoxide (oxyethidium fluorescence) and found an increase in superoxide activity in the calcified stenotic valves as compared with controls. This study provides further evidence to the growing field of valvular biology that lipids play a critical role in the development of valvular heart disease as well as vascular heart disease.The concept that degenerative aortic valve disease has an active biology has been challenged by a growing number of investigators. There are a number of experimental models testing the effects of a cholesterol diet on the aortic valve. Sarphie12 demonstrated the first histochemical effects of cholesterol on the development of valvular heart disease. Drolet et al11a have also shown that a high cholesterol diet and vitamin D treatment can induce an aortic valve that is stenotic and atherosclerotic. Experimentally, our group has also shown in an in vivo model of hypercholesterolemia that the aortic valve develops atherosclerosis, which calcifies over time secondary to the expression of specific bone matrix markers including osteopontin and Cbfa1, the key transcriptional regulator of bone formation.13–15 O'Brien et al16 and Olsson et al17 have confirmed the presence of lipoproteins in human diseased aortic valves. These animal models, the confirmation of lipids in human valves, and the study by Weiss et al are the first to show that hyperlipidemia by means of a diet or a genetic mouse approach will induce an atherosclerotic valve that mineralizes and stenosis over time.If cholesterol is important in the initiating step in the development of valvular heart disease, then the presence of superoxide as described by Weiss et al provides evidence that endothelial dysfunction is important in the initiation of this disease process. Studies by our group18 and Charest et al19 have also shown that endothelial nitric oxide enzyme activity plays a role in the early valve lesions. Elevated cholesterol decreases the enzyme expression and induces early mineralization in the aortic valve. Therefore, these early studies provide the evidence that aortic valve disease has similar initiating mechanism of oxidative stress that is found in vascular atherosclerosis.The next critical step toward understanding of aortic valve calcification is to determine the signaling mechanisms involved in the development of this disease. The studies from Mohler et al20 and our group21 have shown that the aortic valve calcifies secondary to a bone phenotype. Recent studies from our group22 and Shao et al23 have demonstrated that the mechanism by which calcification develops is activation of the LDL receptor 5 (Lrp5)/Wnt pathway in the vascular and valvular interstitial cells. Our group has also confirmed the upregulation of the Lrp5 receptor in human disease valves from surgical valve repair and replacement. This study demonstrated an incremental increase in the Lrp5 receptor expression in the degenerative mitral valves as compared with the calcified aortic valves.23a Therefore, these studies provide further evidence that the underlying mechanism of degenerative mitral regurgitation and aortic valve stenosis in humans is secondary to the activation of the Lrp5 receptor in the mesenchymal myofibroblast cells present in the cardiac valves and that elevated cholesterol induces the valve to undergo a phenotypic switch to bone-forming cells within the valve leaflets. These studies confirm that the presence of bone formation is the phenotypic expression of calcification in the aortic valve.21 Rosenhek et al24 have shown clinically that an increased burden of calcification is a marker of poor prognosis in the outcome of patients with severe asymptomatic aortic stenosis. Therefore, more calcification correlates with an increase in bone formation in these valves and a worse outcome for these patients. The Figure demonstrates the mechanism for the development of this disease as derived from the findings of all of these cumulative studies. In the presence of risk factors such as elevated cholesterol, the cells in the valve leaflet initiate the osteogenic gene program. Over time, the valve leaflet synthesizes bone matrix, which eventually calcifies and forms bone. Clinically, progressive stenosis develops in the valve leaflet, and the patient has eventual symptoms of shortness of breath, lightheadedness, and chest pain. If the aortic valve has an actual biology that is initiated by elevated cholesterol, then in the future, medical therapy such as statins or angiotensin-converting enzyme inhibitors may slow the progression of this disease. Download figureDownload PowerPointCalcific aortic stenosis: Schematic of the development of aortic valve disease in the presence of elevated cholesterol.If aortic valve disease has an active biology, is there medical therapy for calcific aortic stenosis? The first landmark randomized, prospective trial published in this field, Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE),25 demonstrated that high-dose atorvastatin does not slow the progression of this disease. SALTIRE initiated atorvastatin in patients who had more advanced aortic stenosis as defined by the mean aortic valve area of 1.03 cm2, with heavy burden of calcification as measured by aortic valve calcium scores. Newby et al26 recently acknowledged that the timing of therapy for aortic valve stenosis may play the key role in the future treatment of this disease. The important issue may be treating this disease earlier in its process to slow the progression of bone formation in the aortic valve. In the future, randomized trials for this disease will provide important information similar to the discoveries of vascular atherosclerosis in terms of medications and timing of the disease. There are currently a growing number of trials in progress to test the effects of statins in aortic valve disease, including RAAVE (Rosuvastatin Affecting Aortic Valve Endothelium [Porto, Portugal]), ASTRONOMER (Aortic Stenosis Progression Observation Measuring Effects of Rosuvastatin [Canada]), SEAS (Simvastatin and the Ezetimibe in Aortic Stenosis27 [Europe]), and STOP-AS (Stop Aortic Stenosis [Cleveland Clinic, Cleveland, Ohio]). In 2006, a growing number of epidemiological and experimental studies have confirmed that this disease has an actual biology that is similar to that of vascular atherosclerosis. Furthermore, this disease process is ready for an aggressive change from the paradigm of considering this disease as an atherosclerotic process. Early detection of this sclerotic lesion may provide an inexpensive method of detecting atherosclerosis with a stethoscope and opens another avenue for the possibility of treating the atherosclerotic process earlier and slowing the progression of aortic stenosis.The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.DisclosuresDr Rajamannan is an inventor on a patent owned by the Mayo Clinic entitled: "Method for Slowing Heart Valve Degeneration." Dr. Rajamannan does not receive any royalties from this patent.FootnotesCorrespondence to Nalini M. Rajamannan, MD, Valve Director, Bluhm Cardiovascular Institute, Northwestern University, Feinberg School of Medicine, 300 East Chicago Ave, Tarry 12–717, Chicago, IL 60611. E-mail [email protected] References 1 Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Nishimura R, Page RL, Riegel B. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation. 2006; 114: e84–e231.LinkGoogle Scholar2 Ross J Jr, Braunwald E. Aortic stenosis. Circulation. 1968; 38 (Suppl I): I-61–I-67.CrossrefMedlineGoogle Scholar3 Herrick JB. A Short History of Cardiology. Springfield, Ill: Thomas; 1942: 231–232.Google Scholar4 Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM. Clinical factors associated with calcific aortic valve disease: Cardiovascular Health Study. J Am Coll Cardiol. 1997; 29: 630–634.CrossrefMedlineGoogle Scholar5 Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol. 2001; 88: 693–695.CrossrefMedlineGoogle Scholar6 Palta S, Pai AM, Gill KS, Pai RG. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation. 2000; 101: 2497–2502.CrossrefMedlineGoogle Scholar7 Peltier M, Trojette F, Sarano ME, Grigioni F, Slama MA, Tribouilloy CM. Relation between cardiovascular risk factors and nonrheumatic severe calcific aortic stenosis among patients with a three-cuspid aortic valve. Am J Cardiol. 2003; 91: 97–99.CrossrefMedlineGoogle Scholar8 Chui MC, Newby DE, Panarelli M, Bloomfield P, Boon NA. Association between calcific aortic stenosis and hypercholesterolemia: is there a need for a randomized controlled trial of cholesterol-lowering therapy? Clin Cardiol. 2001; 24: 52–55.CrossrefMedlineGoogle Scholar9 Pohle K, Maffert R, Ropers D, Moshage W, Stilianakis N, Daniel WG, Achenbach S. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation. 2001; 104: 1927–1932.CrossrefMedlineGoogle Scholar10 Weiss RM, Ohashi M, Miller JD, Young SG, Heistad DD. Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation. 2006; 114; 2065–2069.LinkGoogle Scholar11 Sanan DA, Newland DL, Tao R, Marcovina S, Wang J, Mooser V, Hammer RE, Hobbs HH. Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(a). Proc Natl Acad Sci U S A. 1998; 95: 4544–4549.CrossrefMedlineGoogle Scholar11A Drolet MC, Arsenault M, Couet J. Experimental aortic valve stenosis in rabbits. J Am Coll Cardiol. 2003; 41: 1211–1217.CrossrefMedlineGoogle Scholar12 Sarphie TG. A cytochemical study of the surface properties of aortic and mitral valve endothelium from hypercholesterolemic rabbits. Exp Mol Pathol. 1986; 281–296.MedlineGoogle Scholar13 Rajamannan NM, Sangiorgi G, Springett M, Arnold K, Mohacsi T, Spagnoli LG, Edwards WD, Tajik AJ, Schwartz RS. Experimental hypercholesterolemia induces apoptosis in the aortic valve. J Heart Valve Dis. 2001; 10: 371–374.MedlineGoogle Scholar14 Rajamannan NM, Subramaniam M, Springett M, Sebo TC, Niekrasz M, McConnell JP, Singh RJ, Stone NJ, Bonow RO, Spelsberg TC. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation. 2002; 105: 2260–2265.LinkGoogle Scholar15 Rajamannan NM. Calcific aortic stenosis: medical and surgical management in the elderly. Curr Treat Options Cardiovasc Med. 2005; 7: 437–442.CrossrefMedlineGoogle Scholar16 O'Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, Otto CM. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol. 1996; 16: 523–532.CrossrefMedlineGoogle Scholar17 Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol. 1999; 19: 1218–1222.CrossrefMedlineGoogle Scholar18 Rajamannan NM, Subramaniam M, Stock SR, Stone NJ, Springett M, Ignatiev KI, McConnell JP, Singh RJ, Bonow RO, Spelsberg TC. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart. 2005; 91: 806–810.CrossrefMedlineGoogle Scholar19 Charest A, Pepin A, Shetty R, Cote C, Voisine P, Dagenais F, Pibarot P, Mathieu P. Distribution of SPARC during neovascularization of degenerative aortic stenosis. Heart. May 18, 2006. DOI:10.1136/hrt.2005.086595. Available at: http://heart.bmjjournals.com. Accessed October 19, 2006.Google Scholar20 Mohler ER III, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS. Bone formation and inflammation in cardiac valves. Circulation. 2001; 103: 1522–1528.CrossrefMedlineGoogle Scholar21 Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Donovan J, Springett M, Orszulak T, Fullerton DA, Tajik AJ, Bonow RO, Spelsberg T. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation. 2003; 107: 2181–2184.LinkGoogle Scholar22 Rajamannan NM, Subramaniam M, Caira F, Stock SR, Spelsberg TC. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation. 2005; 112 (Suppl I): I-229–I-234.LinkGoogle Scholar23 Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest. 2005; 115: 1210–1220.CrossrefMedlineGoogle Scholar23A Caira FC, Stock SR, Gleason TG, McGee EC, Huang J, Bonow RO, Spelsberg TC, McCarthy PM, Rahimtoola SH, Rajamannan NM. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol. 2006; 47: 1707–1712.CrossrefMedlineGoogle Scholar24 Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M, Maurer G, Baumgartner H. Predictors of outcome in severe asymptomatic aortic stenosis. N Engl J Med. 2000; 343: 611–617.CrossrefMedlineGoogle Scholar25 Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005; 352: 2389–2397.CrossrefMedlineGoogle Scholar26 Newby DE, Cowell SJ, Boon NA. Emerging medical treatments for aortic stenosis: statins, angiotensin converting enzyme inhibitors, or both? Heart. 2006; 92: 729–734.CrossrefMedlineGoogle Scholar27 Rossebo A, Pederson T, Skjaerpe T. Design of the Simvastatin and Ezetimide in Aortic Stenosis (SEAS) Study. Atherosclerosis. 2003; 170: 253.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Lassalle F, Rosa M, Staels B, Van Belle E, Susen S and Dupont A (2022) Circulating Monocyte Subsets and Transcatheter Aortic Valve Replacement, International Journal of Molecular Sciences, 10.3390/ijms23105303, 23:10, (5303) Vaidya K, Donnelly M, Mahmut A, Jang J, Gee T, Aibo M, Bossong R, Hall C, Samb S, Chen J and Butcher J (2022) Rac1 mediates cadherin-11 induced cellular pathogenic processes in aortic valve calcification, Cardiovascular Pathology, 10.1016/j.carpath.2022.107414, 58, (107414), Online publication date: 1-May-2022. Vaidya K, Donnelly M, Gee T, Ibrahim Aibo M, Byers S and Butcher J (2020) Induction of aortic valve calcification by celecoxib and its COX-2 independent derivatives is glucocorticoid-dependent, Cardiovascular Pathology, 10.1016/j.carpath.2019.107194, 46, (107194), Online publication date: 1-May-2020. Ferrari G and Grau J (2019) Diagnostic and Therapeutic Targets for Aortic Valve and Ascending Aorta Pathologies: Challenges and Opportunities Surgical Management of Aortic Pathology, 10.1007/978-3-7091-4874-7_41, (591-608), . Liu B, Xu T, Xu X, Cui Y and Xing X (2018) Biglycan promotes the chemotherapy resistance of colon cancer by activating NF-κB signal transduction, Molecular and Cellular Biochemistry, 10.1007/s11010-018-3365-1, 449:1-2, (285-294), Online publication date: 1-Dec-2018. Lee S and Choi J (2018) Involvement of inflammatory responses in the early development of calcific aortic valve disease: lessons from statin therapy, Animal Cells and Systems, 10.1080/19768354.2018.1528175, 22:6, (390-399), Online publication date: 2-Nov-2018. Rajamannan N (2018) Osteocardiology: Endochondral Bone Formation Osteocardiology, 10.1007/978-3-319-64994-8_5, (45-56), . Martin-Rojas T, Mourino-Alvarez L, Gil-Dones F, de la Cuesta F, Rosello-Lleti E, Laborde C, Rivera M, Lopez-Almodovar L, Lopez J, Akerstrom F, Padial L and Barderas M (2017) A clinical perspective on the utility of alpha 1 antichymotrypsin for the early diagnosis of calcific aortic stenosis, Clinical Proteomics, 10.1186/s12014-017-9147-z, 14:1, Online publication date: 1-Dec-2017. Alnabelsi T, Alhamshari Y, Mulki R, Codolosa J, Koshkelashvili N, Goykhman I, Pressman G and Romero-Corral A (2016) Relation Between Epicardial Adipose and Aortic Valve and Mitral Annular Calcium Determined by Computed Tomography in Subjects Aged ≥65 Years, The American Journal of Cardiology, 10.1016/j.amjcard.2016.07.012, 118:7, (1088-1093), Online publication date: 1-Oct-2016. Shuvy M, Abedat S, Mustafa M, Duvdevan N, Meir K, Beeri R, Lotan C and Aikawa E (2015) Cellular Changes during Renal Failure-Induced Inflammatory Aortic Valve Disease, PLOS ONE, 10.1371/journal.pone.0129725, 10:6, (e0129725) Parisi V, Leosco D, Ferro G, Bevilacqua A, Pagano G, de Lucia C, Perrone Filardi P, Caruso A, Rengo G and Ferrara N (2015) The lipid theory in the pathogenesis of calcific aortic stenosis, Nutrition, Metabolism and Cardiovascular Diseases, 10.1016/j.numecd.2015.02.001, 25:6, (519-525), Online publication date: 1-Jun-2015. Neufeld E, Zadrozny L, Phillips D, Aponte A, Yu Z and Balaban R (2014) Decorin and biglycan retain LDL in disease-prone valvular and aortic subendothelial intimal matrix, Atherosclerosis, 10.1016/j.atherosclerosis.2013.12.038, 233:1, (113-121), Online publication date: 1-Mar-2014. Horstkotte D, Prinz C and Piper C (2013) Der "asymptomatische" Patient mit chronischem HerzklappenfehlerThe "asymptomatic" patient with chronic acquired heart valve disease, Der Internist, 10.1007/s00108-012-3092-8, 54:1, (7-17), Online publication date: 1-Jan-2013. Song R, Zeng Q, Ao L, Yu J, Cleveland J, Zhao K, Fullerton D and Meng X (2012) Biglycan Induces the Expression of Osteogenic Factors in Human Aortic Valve Interstitial Cells via Toll-Like Receptor-2, Arteriosclerosis, Thrombosis, and Vascular Biology, 32:11, (2711-2720), Online publication date: 1-Nov-2012. Sun L, Chandra S, Sucosky P and Aikawa E (2012) Ex Vivo Evidence for the Contribution of Hemodynamic Shear Stress Abnormalities to the Early Pathogenesis of Calcific Bicuspid Aortic Valve Disease, PLoS ONE, 10.1371/journal.pone.0048843, 7:10, (e48843) Martín-Rojas T, Gil-Dones F, Lopez-Almodovar L, Padial L, Vivanco F and Barderas M (2012) Proteomic Profile of Human Aortic Stenosis: Insights into the Degenerative Process, Journal of Proteome Research, 10.1021/pr2005692, 11:3, (1537-1550), Online publication date: 2-Mar-2012. New S, Aikawa E and Towler D (2011) Molecular Imaging Insights Into Early Inflammatory Stages of Arterial and Aortic Valve Calcification, Circulation Research, 108:11, (1381-1391), Online publication date: 27-May-2011. Thiago L, Tsuj S, Atallah Á, Puga M and Góis A (2011) Statins for progression of aortic valve stenosis and the best evidence for making decisions in health care, Sao Paulo Medical Journal, 10.1590/S1516-31802011000100008, 129:1, (41-45), Online publication date: 6-Jan-2011. Kwon J, Park C, Sa Y, Kim Y, Moon S and Kim C (2010) Upregulation of Connexin43 Expression in Mitral Valves in a Rabbit Model of Hypercholesterolemia, The Korean Journal of Thoracic and Cardiovascular Surgery, 10.5090/kjtcs.2010.43.4.356, 43:4, (356-363), Online publication date: 5-Aug-2010. Kamalesh M, Ng C and Eckert G (2009) Retracted: Relation of Atherosclerotic Cardiovascular Events to Progression of Aortic Stenosis in Older Men, Clinical Cardiology, 10.1002/clc.20541, 33:2, (119-121), Online publication date: 1-Feb-2010. Lehmann S, Walther T, Kempfert J, Rastan A, Garbade J, Dhein S and Mohr F (2009) Mechanical Strain and the Aortic Valve: Influence on Fibroblasts, Extracellular Matrix, and Potential Stenosis, The Annals of Thoracic Surgery, 10.1016/j.athoracsur.2009.07.025, 88:5, (1476-1483), Online publication date: 1-Nov-2009. Barrick C, Roberts R, Rojas M, Rajamannan N, Suitt C, O'Brien K, Smyth S and Threadgill D (2009) Reduced EGFR causes abnormal valvular differentiation leading to calcific aortic stenosis and left ventricular hypertrophy in C57BL/6J but not 129S1/SvImJ mice, American Journal of Physiology-Heart and Circulatory Physiology, 10.1152/ajpheart.00866.2008, 297:1, (H65-H75), Online publication date: 1-Jul-2009. Rajamannan N (2009) Cellular Pathogenesis of Degenerative Valvular Heart Disease: From Calcific Aortic Stenosis to Myxomatous Mitral Valve Disease Valvular Heart Disease, 10.1007/978-1-59745-411-7_2, (37-57), . de Graft-Johnson J and Gleason T (2007) Evaluation and management of aortic valve and root disease, Current Treatment Options in Cardiovascular Medicine, 10.1007/s11936-007-0041-2, 9:6, (465-472), Online publication date: 1-Dec-2007. Chaliki H, Brown M, Sundt T and Tajik A (2014) Timing of operation in asymptomatic severe aortic stenosis, Expert Review of Cardiovascular Therapy, 10.1586/14779072.5.6.1065, 5:6, (1065-1071), Online publication date: 1-Nov-2007. Mathieu P, Després J and Pibarot P (2007) The 'valvulo-metabolic' risk in calcific aortic valve disease, Canadian Journal of Cardiology, 10.1016/S0828-282X(07)71008-5, 23, (32B-39B), Online publication date: 1-Oct-2007. November 7, 2006Vol 114, Issue 19 Advertisement Article InformationMetrics https://doi.org/10.1161/CIRCULATIONAHA.106.657759PMID: 17088474 Originally publishedNovember 7, 2006 KeywordsatherosclerosischolesterolagingvalvespathologyEditorialsstenosisPDF download Advertisement SubjectsAnimal Models of Human DiseaseCardiovascular SurgeryEpidemiologyLipids and CholesterolPathophysiologySecondary Prevention
Referência(s)